Latest News and Press Releases

- Eltoprazine Phase 2b clinical program on track to commence in 2Q 2015 - - Management to host conference call and webcast on Wednesday, May 27, 2015 at 5:00 p.m. EDT - SAN FRANCISCO and...

-Marcum Microcap Conference Presentation on May 28, 2015, at 2:30 p.m. EDT / 11:30 a.m. PDT- -LD Micro Invitational Presentation and Webcast on June 2, 2015, at 1:30 p.m. EDT / 10:30 a.m....

Collaboration Using Renishaw Plc's Convection-Enhanced Delivery Device Demonstrated MANF Can be Precisely Delivered to Parkinson's-Associated Brain Areas Delivery and Distribution Data Solidifies...

- Catalent to Utilize Proprietary GPEx® Platform for Production of High Performance MANF Expressing Cell Line - - cGMP Production of MANF to Enable Program Advancement Into Human Clinical...

SAN FRANCISCO and GENEVA, Switzerland, May 13, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic...

-MSPrecise blood diagnostic shows statistically significant sensitivity and specificity for classifying presentation of multiple sclerosis- -Data supports further research into blood-based...

- Study conducted by leading researchers at University of Miami - - Data demonstrate MANF preserves photoreceptor cells and light-sensing function - SAN FRANCISCO and GENEVA, May 7, 2015 (GLOBE...

SAN FRANCISCO and GENEVA, May 5, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for...

SAN FRANCISCO and GENEVA, April 29, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for...

SAN FRANCISCO and GENEVA, April 27, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic...